Work

Figure S1 from Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas

Year: 2023

Type: other

Abstract: (A) Immunoblotting of BCL-2 levels in representative MCL and DLBCL cell lines with actin as a loading control. Cell viability assays were performed using the Celltiter-Glo Luminescent Cell Viability Assay in representative GCB-DLBCL (B), non-GCB-DLBCL (C), and MCL (D) cell lines treated with increasing concentrations of venetoclax.

DOI: 10.1158/1078-0432.22467464

Authors: Lan V. Pham, Shengjian Huang, Hui Zhang, Jun Zhang, Taylor Bell, Shouhao Zhou, Elizabeth Pogue, Zhiyong Ding, Laura Lam, Jason Westin, R. Eric Davis, Ken H. Young, L. Jeffrey Medeiros, Richard J. Ford, Krystle Nomie, Leo Zhang, Michael Wang

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362432827

Cites:

Cited by:

Related to: 10